The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, launched the National Network for Drugs and Medical Products Safety During Pregnancy and Breastfeeding on the sidelines of the SFDA's participation in the Global Health Exhibition. The Exhibition was held in Riyadh from October 27–30, with the participation of more than 2,000 entities from around the world.

The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, launched the Regulatory AI System for Incoming Drugs (RASID) smart service, which utilizes artificial intelligence technologies to regulate and control the entry of controlled medications carried by travelers. The launch took place during the Global Health Exhibition, held from October 27 to 30 at the Riyadh International Convention and Exhibition Center in Malham. 

The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, launched an AI-powered model for predicting drug shortages in the Kingdom of Saudi Arabia. The launch took place during the Global Health Exhibition, held from October 27 to 30. It highlights the SFDA's commitment to enhance drug monitoring and proactively address any potential shortages.

The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, launched the “Saudi Pharmacopoeia” on the sidelines of the SFDA's participation in the Global Health Exhibition (GHE) held at the Riyadh Exhibition and Convention Center in Malham from October 27 to 30, under the theme “Invest in Health.”

The International Coalition of Medicines Regulatory Authorities (ICMRA) announced the full membership of the Kingdom of Saudi Arabia, represented by the Saudi Food and Drug Authority (SFDA). This achievement makes the SFDA the first regulatory authority from the Middle East and North Africa (MENA) to become full member in ICMRA.

H.E. Dr. Hisham S. Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), met at the Authority’s headquarters in Riyadh with several chief executives and representatives of local and international pharmaceutical companies to discuss key issues and opportunities that will contribute to the growth and support of the pharmaceutical sector in the Kingdom.

The Saudi Food and Drug Authority (SFDA), has approved the registration of Qalsody (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. ALS is a rare motor neuron disorder that progressively affects the nerve cells responsible for voluntary movement, leading to muscle weakness, and eventually, a loss of mobility. This approval reflects the SFDA’s continued efforts to facilitate access to treatments for rare diseases, with Qalsody designated under the Orphan Drug Program.